{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T11:11:07Z","timestamp":1762254667446,"version":"build-2065373602"},"reference-count":42,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Haematology"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.beha.2023.101517","type":"journal-article","created":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T03:20:08Z","timestamp":1697512808000},"page":"101517","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["When to use which molecular prognostic scoring system in the management of patients with MDS?"],"prefix":"10.1016","volume":"36","author":[{"given":"Tariq","family":"Kewan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan Philipp","family":"Bewersdorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmelo","family":"Gurnari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuoer","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maximilian","family":"Stahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amer M.","family":"Zeidan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.beha.2023.101517_bib1","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2023.101517_bib2","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1182\/blood.2019000942","article-title":"Genetics of progression from MDS to secondary leukemia","volume":"136","author":"Menssen","year":"2020","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.beha.2023.101517_bib3","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1056\/NEJMra1904794","article-title":"Myelodysplastic syndromes","volume":"383","author":"Cazzola","year":"2020","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.beha.2023.101517_bib4","doi-asserted-by":"crossref","first-page":"6296","DOI":"10.1182\/blood-2008-09-038935","article-title":"How I treat patients with myelodysplastic syndromes","volume":"113","author":"Stone","year":"2009","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2023.101517_bib5","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s40266-021-00881-3","article-title":"Management of the older patient with myelodysplastic syndrome","volume":"38","author":"Shallis","year":"2021","journal-title":"Drugs Aging"},{"issue":"7","key":"10.1016\/j.beha.2023.101517_bib6","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1182\/blood-2016-02-700054","article-title":"Time-dependent changes in mortality and transformation risk in MDS","volume":"128","author":"Pfeilstocker","year":"2016","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2023.101517_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/genes12081144","article-title":"The genetics of myelodysplastic syndromes: clinical relevance","volume":"12","author":"Chiereghin","year":"2021","journal-title":"Genes"},{"issue":"1","key":"10.1016\/j.beha.2023.101517_bib8","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1159\/000488712","article-title":"The molecular pathology of myelodysplastic syndrome","volume":"86","author":"Haferlach","year":"2019","journal-title":"Pathobiology"},{"issue":"2","key":"10.1016\/j.beha.2023.101517_bib9","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/leu.2013.336","article-title":"Landscape of genetic lesions in 944 patients with myelodysplastic syndromes","volume":"28","author":"Haferlach","year":"2014","journal-title":"Leukemia"},{"issue":"26","key":"10.1016\/j.beha.2023.101517_bib10","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1056\/NEJMoa1013343","article-title":"Clinical effect of point mutations in myelodysplastic syndromes","volume":"364","author":"Bejar","year":"2011","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.beha.2023.101517_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23052802","article-title":"Personalized risk schemes and machine learning to empower genomic prognostication models in myelodysplastic syndromes","volume":"23","author":"Awada","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"12","key":"10.1016\/j.beha.2023.101517_bib12","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2023.101517_bib13","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"issue":"30","key":"10.1016\/j.beha.2023.101517_bib14","doi-asserted-by":"crossref","first-page":"7594","DOI":"10.1200\/JCO.2005.01.7038","article-title":"Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making","volume":"23","author":"Malcovati","year":"2005","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.beha.2023.101517_bib15","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood.V99.3.840","article-title":"Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients","volume":"99","author":"Onida","year":"2002","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2023.101517_bib16","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1038\/leu.2016.138","article-title":"Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes","volume":"30","author":"Nazha","year":"2016","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.beha.2023.101517_bib17","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular international prognostic scoring system for myelodysplastic syndromes","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evidence"},{"key":"10.1016\/j.beha.2023.101517_bib18","article-title":"Prognostication in myelodysplastic syndromes (neoplasms): molecular risk stratification finally coming of age","author":"Xie","year":"2022","journal-title":"Blood Rev"},{"issue":"3","key":"10.1016\/j.beha.2023.101517_bib19","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/bjh.13450","article-title":"Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry","volume":"170","author":"de Swart","year":"2015","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.beha.2023.101517_bib20","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s12185-017-2250-0","article-title":"Validation of the revised International Prognostic Scoring System in patients with myelodysplastic syndrome in Japan: results from a prospective multicenter registry","volume":"106","author":"Kawabata","year":"2017","journal-title":"Int J Hematol"},{"issue":"7","key":"10.1016\/j.beha.2023.101517_bib21","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/ajh.23454","article-title":"Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes","volume":"88","author":"Mishra","year":"2013","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1016\/j.beha.2023.101517_bib22","doi-asserted-by":"crossref","first-page":"e242","DOI":"10.1038\/bcj.2014.62","article-title":"Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q)","volume":"4","author":"Sekeres","year":"2014","journal-title":"Blood Cancer J"},{"issue":"5","key":"10.1016\/j.beha.2023.101517_bib23","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1600-0609.2008.01124.x","article-title":"Is International Prognostic Scoring System (IPSS) still standard in predicting prognosis in patients with myelodysplastic syndrome? External validation of the WHO Classification-Based Prognostic Scoring System (WPSS) and comparison with IPSS","volume":"81","author":"Park","year":"2008","journal-title":"Eur J Haematol"},{"issue":"7","key":"10.1016\/j.beha.2023.101517_bib24","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1038\/leu.2015.55","volume":"29","author":"Della Porta","year":"2015","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.beha.2023.101517_bib25","doi-asserted-by":"crossref","first-page":"e224","DOI":"10.3324\/haematol.2015.140962","article-title":"The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure","volume":"101","author":"Nazha","year":"2016","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.beha.2023.101517_bib26","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1182\/blood-2016-07-724930","article-title":"Defining risk in MDS over time","volume":"128","author":"Yoshimi","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2023.101517_bib27","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/17474086.2022.2029698","article-title":"How low risk are low risk myelodysplastic syndromes?","volume":"15","author":"DeZern","year":"2022","journal-title":"Expert Rev Hematol"},{"issue":"1","key":"10.1016\/j.beha.2023.101517_bib28","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1182\/hematology.2021000276","article-title":"Have we reached a molecular era in myelodysplastic syndromes?","volume":"2021","author":"Voso","year":"2021","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"10","key":"10.1016\/j.beha.2023.101517_bib29","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/s41591-020-1008-z","article-title":"Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes","volume":"26","author":"Bernard","year":"2020","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.beha.2023.101517_bib30","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1080\/10428194.2021.2018579","article-title":"Prognostic scoring systems and risk stratification in myelodysplastic syndrome: focus on integration of molecular profile","volume":"63","author":"Ball","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.beha.2023.101517_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.106238","article-title":"A multimodal analysis of genomic and RNA splicing features in myeloid malignancies","volume":"26","author":"Durmaz","year":"2023","journal-title":"iScience"},{"issue":"33","key":"10.1016\/j.beha.2023.101517_bib32","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.20.02810","article-title":"Personalized prediction model to risk stratify patients with myelodysplastic syndromes","volume":"39","author":"Nazha","year":"2021","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.beha.2023.101517_bib33","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1200\/JCO.20.01659","article-title":"Classification and personalized prognostic assessment on the basis of clinical and genomic features in myelodysplastic syndromes","volume":"39","author":"Bersanelli","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2023.101517_bib34","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.22.01784","article-title":"Real-world validation of molecular international prognostic scoring system for myelodysplastic syndromes","author":"Sauta","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2023.101517_bib35","article-title":"Validation of the molecular international prognostic scoring system in patients with myelodysplastic syndromes","author":"Kewan","year":"2023","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2023.101517_bib36","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/s41375-023-01820-4","article-title":"Outcome prediction in myelodysplastic neoplasm undergoing hematopoietic cell transplant in the molecular era of IPSS-M","volume":"37","author":"Gurnari","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2023.101517_bib37","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2023020108","article-title":"IPSS-M in myelodysplastic neoplasms arising from aplastic anemia and paroxysmal nocturnal hemoglobinuria","author":"Gurnari","year":"2023","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2023.101517_bib38","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/s41375-023-01831-1","article-title":"Risk prediction in MDS: independent validation of the IPSS-M-ready for routine?","volume":"37","author":"Baer","year":"2023","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.beha.2023.101517_bib39","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s40164-022-00328-4","article-title":"IPSS-M has greater survival predictive accuracy compared with IPSS-R in persons >\/= 60 years with myelodysplastic syndromes","volume":"11","author":"Wu","year":"2022","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.beha.2023.101517_bib40","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-023-01910-3","article-title":"Assessment and validation of the molecular international prognostic scoring system for myelodysplastic syndromes","author":"Aguirre","year":"2023","journal-title":"Leukemia"},{"year":"2022","series-title":"Molecular patterns identify distinct subclasses of myeloid neoplasia","author":"Tariq Kewan","key":"10.1016\/j.beha.2023.101517_bib41"},{"issue":"2","key":"10.1016\/j.beha.2023.101517_bib42","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/bjh.17909","article-title":"'We cannot paint them all with the same brush': the need for a better definition of patients with myelodysplastic syndromes for clinical trial design","volume":"196","author":"Gurnari","year":"2022","journal-title":"Br J Haematol"}],"container-title":["Best Practice &amp; Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692623000786?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692623000786?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:09:53Z","timestamp":1761498593000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692623000786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S1521692623000786"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2023.101517","relation":{},"ISSN":["1521-6926"],"issn-type":[{"type":"print","value":"1521-6926"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"When to use which molecular prognostic scoring system in the management of patients with MDS?","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2023.101517","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101517"}}